国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (10): 792-795.doi: １０．３７６０／ｃｍａ．ｊ．ｉｓｓｎ．１６７３４２２Ｘ．２０１４．１０．０２２

• 论著 • 上一篇    下一篇

晚期上皮性卵巢癌新辅助化疗的疗效分析

赵晓艳   

  1. ０３４０００山西省忻州市中医医院妇产科
  • 出版日期:2014-10-29 发布日期:2014-10-11
  • 通讯作者: 赵晓艳，Ｅｍａｉｌ：１２８６０８０２０７＠ｑｑ．ｃｏｍ E-mail:１２８６０８０２０７＠ｑｑ．ｃｏｍ

Observation on the clinical efficacy of neoadjuvant chemotherapy in the treatment of patients with advanced epithelial ovarian cancer

 ZHAO  Xiao-Yan   

  1. ＤｅｐａｒｔｍｅｎｔｏｆＯｂｓｔｅｔｒｉｃｓａｎｄＧｙｎｅｃｏｌｏｇｙ，ＸｉｎｚｈｏｕＨｏｓｐｉｔａｌ
    ｏｆＴｒａｄｉｔｉｏｎａｌＣｈｉｎｅｓｅＭｅｄｉｃｉｎｅ，Ｘｉｎｚｈｏｕ０３４０００，Ｃｈｉｎａ
  • Online:2014-10-29 Published:2014-10-11
  • Contact: ＺｈａｏＸｉａｏｙａｎ E-mail:１２８６０８０２０７＠ｑｑ．ｃｏｍ

PDF

1285

被引次数

3

摘要： 目的　探讨新辅助化疗治疗晚期上皮性卵巢癌的临床疗效。方法　回顾性分析２００６年５ 月至２０１０年３月山西医科大学附属肿瘤医院收治的６０例Ⅲ～Ⅳ期上皮性卵巢癌患者，按治疗方法的不同 将其分为观察组与对照组各３０例，观察组采用新辅助化疗，对照组不采用新辅助化疗。通过观察疗效、残 留灶大小、手术时间、术中出血量、血清糖类抗原１２５（ＣＡ１２５）水平等，评价新辅助化疗在上皮性卵巢癌中 的疗效。结果　观察组的总有效率为６０．０％，最佳减灭数２１例（７０．０％），显著高于对照组（χ ２＝５．４５５， Ｐ＜０．０５）。观察组ＣＡ１２５水平［（１６５．２６±４３．２７）Ｕ／ｍｌ∶（３３９．１３±５１．８６）Ｕ／ｍｌ，ｔ＝１４．１００，Ｐ＜０．０５］、手 术时间［（１２７．２１±２７．６２）ｍｉｎ∶（１８９．３３±４５．８７）ｍｉｎ，ｔ＝１０．１１３，Ｐ＜０．０５］、术中平均出血量［（４０８．５０± １１２．６２）ｍｌ∶（５９０．６０±１６２．４１）ｍｌ，ｔ＝５．０４７，Ｐ＜０．０５］均低于对照组。观察组的５年生存率为３６．７％，显 著高于对照组５年生存率（２６．７％），差异有统计学意义（χ ２＝８．４９２，Ｐ＝０．０３６）。结论　新辅助化疗能够 改善晚期上皮性卵巢癌的治疗效果。

关键词: 　卵巢肿瘤, 化学疗法, 辅助

Abstract: ObjectiveTo explore the clinical efficacy of neoadjuvant chemotherapy on advanced epithelial ovarian cancer. MethodsFrom May 2006 to March 2010, 60 patients with ⅢⅣ stage advanced epithelial ovarian cancer were collected in Affiliated Cancer Hospital of Shanxi Medical University, which were divided into two groups based on different treatment methods. The observation group used the neoadjuvant chemotherapy, but the control group did not use it. The efficacy, operation time, blood loss, size of residual disease and the level of CA125 were observed to evaluate the safety and clinical efficacy of neoadjuvant chemotherapy. ResultsThe total effective rate in the observation group was 60.0%. The satisfied cytoreductive rate was 70.0%, which was significantly higher than the control group (χ2=5.455, P<0.05). The mean operative time (127.21±27.62) min (t=10.113, P＜0.05), intraoperative mean blood loss (408.5±112.62) ml (t=5.047, P＜0.05) and the level of CA125 (165.26±43.27) U/ml (t=14.100, P<0.05) in the observation group were significantly lower than the control group［189.33±45.81) min，(590.6±162.41) ml，(339.13±51.86) U/ml］. Five year survival rates of the observation group and control group were 36.7% and 26.7% respectively, with significant difference (χ2=8.492, P=0.036). ConclusionNeoadjuvant chemotherapy can play a positive role in the treatment of the patients with advanced epithelial ovarian cancer.

Key words: Ovarian neoplasms, Chemotherapy, adjuvant